Skip to main content

Semaglutide vs Retatrutide

Both Semaglutide and Retatrutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Semaglutide

Evidence A+

Semaglutide (Ozempic / Wegovy)

A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.

View full Semaglutide profile →

Retatrutide

Evidence A

Retatrutide (LY3437943)

Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.

View full Retatrutide profile →

Side-by-Side

AttributeSemaglutideRetatrutide
Evidence GradeA+A
FDA StatusFDA-approved for weight management and type 2 diabetesNot FDA-approved — Phase 3 trials (TRIUMPH program) for obesity
Typical Dose0.25–2.4 mg weekly (subcutaneous injection)Trial range: 1–12 mg weekly (subcutaneous)
Clinics Indexed2,28512
Categoriesweight-loss, metabolicweight-loss, metabolic

Key reported benefits — Semaglutide

  • Significant weight loss
  • Appetite suppression
  • Blood sugar control
  • Cardiovascular benefit

Key reported benefits — Retatrutide

  • Highest reported weight loss
  • Triple incretin/glucagon mechanism
  • Metabolic improvement

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons